
Glaukos Reports Positive Phase 4 Results for iDose® TR Combined with Cataract Surgery
Glaukos Reports Positive Phase 4 Results for iDose TR Combined With Cataract Surgery in Glaucoma Patients Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company developing innovative treatments for glaucoma, corneal disorders, and retinal diseases, has announced positive…













